Clinical Trials · NCT06672939
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 150
- Start date
- Nov 2024
- Locations
- 40 sites, 6 countries
- Primary endpoint
- Percent Change from Baseline in Body Mass Index (BMI)